Monogram Orthopaedics Delivers First Surgical Robot

Rhea-AI Summary

Monogram Orthopaedics Inc. (MGRM) achieves a significant revenue milestone by delivering its first surgical robot to a major global distributor. The company's CEO, Ben Sexson, emphasizes the validation of their technology and the pivotal nature of this achievement. Monogram's focus on reconstructive joint procedures and surgical robotics aims to improve the standard of care for orthopedic patients worldwide.

- First Sale to Major Global Distributor Represents Key Revenue Milestone and Paves the Way for Broader Commercialization -

AUSTIN, TX / ACCESSWIRE / November 28, 2023 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), a medical technology company focused on reconstructive joint procedures and surgical robotics, has delivered its first surgical robot to one of the world's largest global robotics distributors.

"Delivering our first robot and realizing our first commercial revenues validates our technology and represents a pivotal milestone for our strategic roadmap," said Ben Sexson, Chief Executive Officer of Monogram Orthopaedics. "Our system is performing at an extremely high level. We now look forward to seeing how our robot competes and scales in the real world. We hope to see the mBôs robot contribute to advancing the standard of care for orthopedic patients worldwide."

Monogram aims to improve the standard of care in orthopedic joint replacement surgery with advanced, next-generation active surgical robotics. Approximately 88% of knee replacement surgeries (the Company's first addressable market) are still manual. The mBôs robot aims to combine safety, ease of use, streamlined cost, novel implant design, broad clinical functionality, and speed to help drive the next wave of robotic adoption in orthopedics.

About Monogram Orthopaedics

Monogram Orthopaedics (NASDAQ: MGRM) is working to develop a product solution architecture with the long-term goal of enabling patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging. The Company has a robot prototype that can autonomously execute optimized paths for high-precision insertion of implants in synthetic bone specimens. Monogram intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures. The Company has not yet made 510(k) premarket notification submissions or obtained 510(k) clearances for its robotic products. FDA approval is required to market these products, and the Company has not obtained FDA approval for any of its robotic products, and it cannot estimate the timing or assure the ability, to obtain such clearances.

Monogram Orthopaedics is working to advance the way orthopedic surgery is done. Our system is being developed to combine personalized knee implants with precision robotic surgical assistants to hopefully give patients a better-fitting knee replacement with minimally invasive surgery. One hundred thousand knee replacements failing each year in a $19.4B market represents an enormous opportunity for us.

To learn more, visit www.monogramorthopedics.com.

Forward-Looking Statements

This press release may include "forward-looking statements.'' To the extent that the information presented in this presentation discusses financial projections, information, or expectations about Monogram Orthopaedics Inc.'s business plans, results of operations, products or markets, or otherwise makes statements about future events, such statements are forward-looking. Such forward-looking statements can be identified by the use of words such as ''should,'' ''may,'' ''intends,'' ''anticipates,'' ''believes,'' ''estimates,'' ''projects,'' ''forecasts,'' ''expects,'' ''plans,'' and ''proposes.''

Although Monogram Orthopaedics Inc. believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading "Risk Factors" and elsewhere in the offering statement filed with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained, and Monogram Orthopaedics Inc. does not undertake any duty to update any forward-looking statements except as may be required by law.

Investor Relations

Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
MGRM@mzgroup.us

SOURCE: MONOGRAM ORTHOPAEDICS INC

View source version on accesswire.com:
https://www.accesswire.com/810651/monogram-orthopaedics-delivers-first-surgical-robot

FAQ

What is the latest milestone achieved by Monogram Orthopaedics Inc. (MGRM)?

Monogram has delivered its first surgical robot to a major global distributor, marking a significant revenue milestone.

Who is the CEO of Monogram Orthopaedics Inc. (MGRM)?

Ben Sexson serves as the Chief Executive Officer of Monogram Orthopaedics Inc.

What is the focus of Monogram Orthopaedics Inc. (MGRM)?

The company is focused on reconstructive joint procedures and surgical robotics to improve the standard of care for orthopedic patients worldwide.

What percentage of knee replacement surgeries is still manual, according to Monogram Orthopaedics Inc. (MGRM)?

Approximately 88% of knee replacement surgeries, which is the company's first addressable market, are still manual.

What are the key goals of the mBôs robot developed by Monogram Orthopaedics Inc. (MGRM)?

The mBôs robot aims to combine safety, ease of use, streamlined cost, novel implant design, broad clinical functionality, and speed to help drive the next wave of robotic adoption in orthopedics.